These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 16024189)

  • 1. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process.
    Won DH; Kim MS; Lee S; Park JS; Hwang SJ
    Int J Pharm; 2005 Sep; 301(1-2):199-208. PubMed ID: 16024189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative solvent-free preparation methods for felodipine surface solid dispersions.
    Kerc J; Srcic S; Kofler B
    Drug Dev Ind Pharm; 1998 Apr; 24(4):359-63. PubMed ID: 9876596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus.
    Joe JH; Lee WM; Park YJ; Joe KH; Oh DH; Seo YG; Woo JS; Yong CS; Choi HG
    Int J Pharm; 2010 Aug; 395(1-2):161-6. PubMed ID: 20580799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of a solid dispersion of felodipine using a solvent wetting method.
    Kim EJ; Chun MK; Jang JS; Lee IH; Lee KR; Choi HK
    Eur J Pharm Biopharm; 2006 Oct; 64(2):200-5. PubMed ID: 16750355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the properties of felodipine solid dispersions prepared by different technologies].
    Shi NQ; Zhang H; Zhang Y; Feng B; Li ZQ; Qi XR
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1067-1073. PubMed ID: 27987515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screen for Inhibitors of Crystal Growth to Identify Desirable Carriers for Amorphous Solid Dispersions Containing Felodipine.
    Fu J; Cui L; Yang C; Xiong H; Ren G; Ma X; Jing Q; Ren F
    AAPS PharmSciTech; 2018 Apr; 19(3):1231-1242. PubMed ID: 29302871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods.
    Li Y; Yang DJ; Chen SL; Chen SB; Chan AS
    Pharm Res; 2008 Mar; 25(3):563-77. PubMed ID: 17828444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of the suitable polymer for supercritical fluid assisted preparation of carvedilol solid dispersions.
    Djuris J; Milovanovic S; Medarevic D; Dobricic V; Dapčević A; Ibric S
    Int J Pharm; 2019 Jan; 554():190-200. PubMed ID: 30414899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions.
    Karavas E; Georgarakis E; Sigalas MP; Avgoustakis K; Bikiaris D
    Eur J Pharm Biopharm; 2007 Jun; 66(3):334-47. PubMed ID: 17267194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.
    Park J; Park HJ; Cho W; Cha KH; Kang YS; Hwang SJ
    Int J Pharm; 2010 Aug; 396(1-2):239-45. PubMed ID: 20599602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions.
    Karavas E; Ktistis G; Xenakis A; Georgarakis E
    Drug Dev Ind Pharm; 2005 Jul; 31(6):473-89. PubMed ID: 16109621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
    Ha ES; Kim JS; Baek IH; Yoo JW; Jung Y; Moon HR; Kim MS
    Drug Des Devel Ther; 2015; 9():4269-77. PubMed ID: 26345723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining SEM, TEM, and micro-Raman techniques to differentiate between the amorphous molecular level dispersions and nanodispersions of a poorly water-soluble drug within a polymer matrix.
    Karavas E; Georgarakis M; Docoslis A; Bikiaris D
    Int J Pharm; 2007 Aug; 340(1-2):76-83. PubMed ID: 17478064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
    Lee KR; Kim EJ; Seo SW; Choi HK
    Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Polymers on the Drug Solubility and Dissolution Enhancement of Poorly Water-Soluble Rivaroxaban.
    Choi MJ; Woo MR; Choi HG; Jin SG
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive Diminution of Particle Size and Amorphization of a Crystalline Drug Attained by Eminent Technology of Solid Dispersion: A Comparative Study.
    Singh G; Sharma S; Gupta GD
    AAPS PharmSciTech; 2017 Jul; 18(5):1770-1784. PubMed ID: 27766512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real time Raman imaging to understand dissolution performance of amorphous solid dispersions.
    Tres F; Treacher K; Booth J; Hughes LP; Wren SA; Aylott JW; Burley JC
    J Control Release; 2014 Aug; 188():53-60. PubMed ID: 24910191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.
    Mahmah O; Tabbakh R; Kelly A; Paradkar A
    J Pharm Pharmacol; 2014 Feb; 66(2):275-84. PubMed ID: 24433426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
    Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
    Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.